EMERGENCY:Rapidly spreading leg or arm weakness — particularly after recent diarrhoea, gastroenteritis, or a viral illness — is a GBS emergency. Do not wait. —call040-46324365immediately — 24 hours, 7 days— 24/7
Guillain-Barré Syndrome: The Paralysis That Starts in the Feet and Climbs — A Reversible Emergency That Requires Immediate Specialist Care in Hyderabad
IVIG, plasmapheresis, and dedicated Neuro-ICU care for GBS at KIMS Neuroscience, Secunderabad, Hyderabad — 24 hours, 7 days.
About This Condition
The Symptom Nobody Expects
A 38-year-old man in Hyderabad had a stomach upset last week — loose stools for three days, now resolved. This morning he noticed his feet feel numb and strangely weak. By afternoon, he is struggling to climb stairs. By evening, both legs are heavy and he is holding the wall to walk.
He comes to KIMS Emergency at 11pm. By the time the neurologist assesses him, his grip strength is also reducing. Nerve conduction studies are performed immediately. The diagnosis: Guillain-Barré Syndrome — an acute immune attack on the peripheral nerves, triggered by the Campylobacter gastroenteritis he had last week.
He is admitted to the KIMS Neuro-ICU that night. His forced vital capacity is monitored every four hours. IVIG is started within six hours of admission.
Without that admission and treatment, within 24–48 hours his breathing muscles could have failed. With it, he will almost certainly walk out of KIMS.
This is GBS — and in India, this exact scenario — gastroenteritis followed by ascending paralysis — is the most common presentation. The incidence of GBS may be higher in developing countries because of prevailing triggers such as diarrhoeal illness and viral infections. Every year, across Hyderabad and Telangana, patients with GBS are admitted to medical wards — initially assessed as "generalised weakness" — and lose critical hours before the diagnosis is made and treatment begins.
At KIMS Neuroscience, the suspicion for GBS is raised immediately in any patient presenting with progressive ascending weakness following a recent infection. This suspicion triggers an urgent nerve conduction study, CSF analysis, and — if confirmed — immediate ICU admission and treatment. Time from diagnosis to first IVIG or plasmapheresis is measured in hours, not days.
GBS Emergency
GBS can progress to respiratory failure within 24–48 hours. Ascending weakness after recent infection needs urgent assessment.
Appointment: 040-44885000Neuro-ICU transfer coordination 24/7What GBS Is — The Peripheral Nerve Attack Explained
The brain and spinal cord — the central nervous system — send signals through the peripheral nerves to the muscles and skin of the limbs, face, and organs. GBS is an immune attack on those peripheral nerves.
The most frequently identified preceding infection is Campylobacter jejuni. The immune system generates antibodies to fight the Campylobacter bacteria. Those antibodies cross-react with proteins on the peripheral nerve myelin sheath — a process called molecular mimicry. The result is inflammation and damage to the insulating myelin around peripheral nerve fibres, disrupting the signal transmission from spine to muscle. In the axonal subtypes of GBS — more common in India — the attack extends to the nerve axon itself, not just the myelin, which is why recovery can be slower.
The distribution of attack follows the peripheral nerves — and because the peripheral nerves serving the legs are the longest in the body, the legs are typically affected first. The paralysis then ascends — moving upward through the legs, trunk, arms, and — in severe cases — to the facial muscles, swallowing muscles, and breathing muscles.
This ascending progression is the diagnostic hallmark of GBS and the source of the life-threatening danger: a patient whose paralysis reaches the diaphragm and intercostal muscles can no longer breathe unaided.
The GBS Subtypes — Why India Sees a Different Pattern
GBS is not a single condition but a spectrum of subtypes defined by the pattern of nerve involvement — and the relevant subtype determines treatment response and prognosis. Two subtypes are particularly important in the Indian context.
AIDP — Acute Inflammatory Demyelinating Polyneuropathy
The most common subtype globally — the immune attack targets peripheral nerve myelin. Nerve conduction studies show slow conduction velocity, reflecting demyelination. AIDP typically responds well to IVIG or plasmapheresis. Recovery is usually better than in axonal subtypes.
AMAN — Acute Motor Axonal Neuropathy
The subtype strongly associated with Campylobacter jejuni infection — and therefore proportionately more common in India. AMAN GBS often shows IVIG failure, unlike AIDP, and is associated with positive ganglioside antibodies. In AMAN, the immune attack targets the axon directly rather than the myelin. Nerve conduction studies show reduced amplitude (reflecting axon loss) rather than slowed velocity. Anti-GM1 and anti-GD1a antibody testing confirms AMAN. Because AMAN may not respond adequately to a single IVIG course, plasmapheresis is often the preferred or escalated treatment at KIMS for confirmed or suspected AMAN. Plasmapheresis is an early treatment option for AMAN GBS, especially in resource-limited settings like India, since its efficacy equals IVIG.
AMSAN — Acute Motor and Sensory Axonal Neuropathy
A more severe axonal subtype with both motor and sensory nerve involvement — associated with worse outcomes and slower recovery.
MFS — Miller Fisher Syndrome
A GBS variant producing the triad of: ophthalmoplegia (inability to move the eyes), ataxia (unsteady gait), and areflexia (absent reflexes). Unlike classic GBS, leg weakness is not the presenting feature — double vision and unsteady walking are. Anti-GQ1b antibody is positive in 90% of MFS cases. Usually self-limiting and benign compared to classic GBS, but requires specialist recognition to avoid misdiagnosis.
Symptoms — What GBS Feels Like and How Fast It Moves
The typical GBS progression follows a predictable pattern — recognising it early is the difference between a routine admission and a respiratory crisis.
The typical GBS progression
Days 1–3 — Tingling and numbness
Tingling and numbness in the feet and toes. The patient often thinks they have been sitting awkwardly. No weakness yet.
Days 3–7 — Progressive weakness begins
Progressive weakness begins in the feet and ankles — difficulty walking on heels, difficulty climbing stairs, legs feeling "heavy." Reflexes diminish and eventually disappear entirely (areflexia — the absence of knee and ankle jerk reflexes is one of the most reliable GBS clinical signs).
Days 7–14 — Ascending weakness
Weakness ascends — reaching thighs, then trunk, then hands and arms. The patient may become unable to stand or walk unaided. Back pain is common and frequently severe — an under-recognised GBS symptom.
Days 14–28 — Plateau phase (most dangerous)
Maximum weakness is reached. This is the most dangerous period for respiratory compromise. Approximately 25% of GBS patients cannot breathe adequately and require ventilation. Swallowing difficulty (bulbar involvement) causes aspiration risk.
After plateau — Recovery begins
Recovery begins — but slowly. The nerve must remyelinate or regenerate. This takes months. The GBS disability scale is measured over 6–12 months.
Other important features
Pain in GBS
Severe pain — in the back, legs, and around the shoulder girdle — is present in up to 89% of GBS patients and is one of the most distressing and under-recognised features. It is often the reason patients present early, before significant weakness is apparent. The pain of GBS precedes the weakness in many cases — a patient with new-onset severe back pain and leg tingling after recent diarrhoea must be assessed for GBS, not just musculoskeletal disease.
Autonomic involvement
Irregular heartbeat, blood pressure fluctuations (extreme highs and lows in rapid succession), sweating abnormalities, and urinary retention are features of autonomic GBS involvement, particularly in severe cases. These autonomic disturbances are one of the main causes of GBS deaths — sudden cardiac arrest from autonomic instability. Continuous cardiac monitoring in the KIMS Neuro-ICU detects and manages these life-threatening fluctuations.
Facial weakness and eye movement problems
Facial diplegia — bilateral facial muscle weakness — occurs in a proportion of GBS patients. In Miller Fisher Syndrome, eye movement paralysis is the presenting feature.
Diagnosis at KIMS
Diagnosis at KIMS
GBS is a clinical and electrophysiological diagnosis. No single test confirms it — the diagnosis is made by combining the clinical picture with nerve conduction studies and CSF analysis.
The clinical assessment
Progressive, ascending, bilateral limb weakness + absent or markedly reduced deep tendon reflexes + history of preceding infection 1–4 weeks prior = GBS until proven otherwise. At KIMS Emergency, this combination triggers an immediate pathway.
Nerve Conduction Studies (NCS) and Electromyography (EMG)
The most important diagnostic investigation. In AIDP, NCS shows slowed conduction velocity and prolonged distal latencies — reflecting demyelination. In AMAN and AMSAN, NCS shows reduced amplitude with preserved velocity — reflecting axon loss. In early GBS (first 2–3 days), NCS may still be normal — a normal NCS in early GBS does not exclude the diagnosis. Serial NCS over days confirms the picture and identifies the subtype.
Lumbar Puncture and CSF Analysis
The classic CSF finding in GBS is albumino-cytological dissociation — elevated CSF protein with normal or near-normal white cell count. Elevated protein reflects nerve root inflammation. This finding supports the diagnosis but may not be present in the first week of illness. Its absence does not exclude GBS.
Anti-ganglioside antibody panel
Anti-GM1 (AMAN), anti-GD1a (AMAN), anti-GQ1b (Miller Fisher Syndrome), anti-GD1b — identifying the specific antibody confirms the GBS subtype and guides treatment decisions. Available at KIMS.
Respiratory monitoring
GBS guidelines identify patients at risk for respiratory failure by measuring Forced Vital Capacity below 20 mL/kg, Maximal Inspiratory Pressure below -30 cm H₂O, or Maximal Expiratory Pressure below 40 cm H₂O — values exceeding these thresholds indicate the need for intensive monitoring or elective ventilation. At KIMS, all admitted GBS patients have bedside spirometry monitored every 4–6 hours until the plateau is clearly established. Elective intubation — before emergency respiratory failure — is the preferred approach when parameters trend toward the threshold.
Treatment
Treatment at KIMS — IVIG, Plasmapheresis, and ICU Care
Both IVIG and plasmapheresis shorten the time to recovery and reduce the peak of disability in GBS. They are equally effective. The choice between them at KIMS is made based on: GBS subtype (AMAN — earlier consideration of plasmapheresis), clinical severity, timing of presentation, and availability.
IVIG (Intravenous Immunoglobulin)
IVIG is given as 0.4g/kg bodyweight daily for 5 days — a total dose of 2g/kg over 5 days. It is preferred in patients with mild-moderate disease, children, and patients for whom central venous access is more difficult. IVIG works by flooding the circulation with normal immunoglobulins that neutralise the pathogenic antibodies attacking the peripheral nerves. The major disadvantage in India is cost — IVIG remains expensive even with biosimilar availability.
Plasmapheresis (Plasma Exchange)
Physically removes the circulating anti-ganglioside and anti-myelin antibodies from the blood by exchanging the patient's plasma for albumin and fresh frozen plasma. The plasma exchange done at a South India centre was 200–250mL of plasma per kilogram weight in five sessions within 7–14 days. Plasmapheresis requires central venous access and a dedicated apheresis machine — available at KIMS. Plasmapheresis is proven as effective as IVIG for GBS treatment in randomised controlled trials and is a particularly appropriate early option in resource settings where cost is a consideration.
What does NOT work in GBS — Corticosteroids
Multiple randomised trials have confirmed that steroids do not benefit GBS and may prolong the disease course. Any patient transferred to KIMS from another centre who has been started on steroids for GBS will have them discontinued. This is one of the most consistent treatment errors in Indian GBS management — steroids are the reflex treatment for "autoimmune neurological disease" in many hospitals without GBS expertise.
Neuro-ICU care at KIMS
GBS ICU management at KIMS is structured around early detection of respiratory and autonomic deterioration — because elective intubation carries a far better outcome than emergency intubation.
Continuous cardiac monitoring for autonomic instability — arrhythmia detection and management
4–6 hourly bedside spirometry — trending FVC toward the intubation threshold
Nasogastric tube feeding — for patients with bulbar weakness and aspiration risk
Mechanical ventilation — for respiratory failure, managed in the KIMS Neuro-ICU with tracheostomy as required for prolonged ventilatory dependence
DVT prevention — immobile patients with GBS are at high thromboembolic risk; pharmacological and mechanical prophylaxis at KIMS
Pressure sore prevention — regular repositioning protocol for paralysed patients
Pain management — neuropathic pain in GBS is severe and requires pregabalin, amitriptyline, or IV opioids in the acute phase; undertreated pain is a major contributor to GBS patient distress in Indian hospitals
Bladder management — urinary retention requiring catheterisation is common in acute GBS
Recovery — What to Expect and When
Important clinical factors associated with poor outcome are age, presence of preceding diarrhoea, and the severity of disability in the early course of disease. The recovery from GBS is real but slow.
Maximum weakness is typically reached at 2–4 weeks. Recovery begins after the plateau — but may be gradual over 6–18 months. About 20% of patients are still unable to walk unaided at 6 months. Most patients with AIDP eventually recover independent walking — the majority within 12 months. AMAN subtype recovery depends on axonal regeneration — which is inherently slower than remyelination, and less complete.
Factors that predict slower recovery at KIMS: Age over 60, preceding Campylobacter diarrhoea (indicating AMAN subtype), very rapid onset to nadir (days rather than weeks), need for ventilation, and severely low amplitude on initial NCS.
The South India GBS experience
A South India tertiary centre found that both plasmapheresis and IVIG were effective in reducing disability grade at all time points — at presentation, immediately post-therapy, and at 4 weeks — with a marginal superiority in plasmapheresis, possibly related to diagnostic delay in presentation. This data from the same regional context as KIMS directly informs how the KIMS team calibrates treatment expectations and discussions with families.
Rehabilitation at KIMS
Physiotherapy from ICU onwards — passive range of motion exercises, positioning to prevent contractures, progressive weight-bearing
Occupational therapy — relearning fine motor tasks, adaptive equipment
Speech therapy — for patients with bulbar involvement and swallowing rehabilitation
Psychological support — GBS is psychologically traumatic; acute paralysis in a previously healthy adult produces anxiety, depression, and PTSD in a significant proportion of patients
Ongoing outpatient review — nerve conduction studies at 3 and 6 months to track recovery and identify those who may benefit from additional IVIG doses
Related Conditions
GBS belongs to the family of demyelinating and inflammatory disorders affecting the peripheral and central nervous systems:
FAQs
Frequently Asked Questions
Legs weakening after a stomach upset. Back pain and tingling feet. This is a neurological emergency — not a muscle problem.
At KIMS Neuroscience, Secunderabad, Hyderabad, every patient presenting with ascending weakness following recent infection is assessed urgently — with bedside nerve conduction studies, CSF analysis, anti-ganglioside antibody panel, and respiratory monitoring. IVIG and plasmapheresis are both available. The Neuro-ICU provides 24-hour respiratory monitoring and ventilatory support. Recovery from GBS takes months — but it starts with the right diagnosis and the right treatment, within hours of arrival.
International enquiries: info@kimsneurosciences.com